Gynecologic Cancer News

Women who miss cancer screenings face higher morbidity and mortality risks, and race may indicate who is more likely to get those screenings, according to a study presented at the North American Menopause Society Annual Meeting.

Hispanic adults had lower rates of overall cancer incidence between 2014 and 2018, but higher rates of liver and stomach cancers compared with whites, according to study results published in CA: A Cancer Journal for Clinicians.

The FDA granted accelerated approval to tisotumab vedotin-tftv for certain women with advanced cervical cancer.

The addition of pembrolizumab to chemotherapy, with or without bevacizumab, significantly improved PFS and OS among women with persistent, recurrent or metastatic cervical cancer, results of the randomized phase 3 KEYNOTE-826 study showed.

When added to chemotherapy, extending the duration of bevacizumab treatment from 15 to 30 months failed to improve progression-free survival or overall survival in patients with epithelial ovarian, fallopian tube or peritoneal cancer, according to a study presented at the ASCO Annual Meeting.

The FDA cleared an investigational new drug application for a T-cell receptor therapy designed to treat adults with solid epithelial cancers that express Kita-Kyushu lung cancer antigen 1.

While on-site at a same-day cancer screening program he helped to implement, Timothy Craig Allen, MD, JD, FCAP, came across a crying woman.

The FDA cleared an investigational new drug application for a chimeric antigen receptor T-cell therapy designed to treat women with relapsed epithelial ovarian cancer.

More than 3 decades after receiving FDA approval, proton beam radiation therapy has failed to find a footing as a go-to treatment for many cancers in the United States.

Women who face economic vulnerability as well as gynecological cancer would benefit from interventions focused on unmet social needs, improving their care and reducing disparities, according to a prospective survey-based study in Cancer.